Mosaic Biomedicals Mosaic Biomedicals is a company founded in 2013 with the aim of developing personalized treatments for cancer with a dual action mechanism that eliminates cancer stem cells and reactivates the tumor's immune system. The compound being developed by Mosaic Biomedicals (MSC-1) is a first-in-class antibody directed against LIF, a pleiotropic cytokine that is overexpressed in certain solid tumors. LIF promotes cancer progression by regulating the tumor microenvironment and tumor-initiating cells. Mosaic, founded by Judit Anido, Joan Seoane and Josep Baselga, is a spin-off of the Vall d'Hebron Institute of Oncology (VHIO), the Catalan Institute of Research and Advanced Studies (ICREA) and the Vall d'Hebron Research Institute (VHIR). Following the founding of Mosaic, the company raised an investment round (Series A) led by: Versant and Caixa Capital Risc. It also has private investors (Business Angels). The public funding that comes from the Retos de Colaboración program, ENISA, CDTI and ERC'S Poc, among others, has been essential in the creation of MOSAIC, to quickly translate scientific development to the benefit of the patient. The company will also become an economic engine to develop value for society that has invested in cancer research. Northern Biologics acquired the company in 2016.